Circle Pharma Announces Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced management will participate in upcoming investor conferences in November:

• LifeSci Growth & Innovation Summit
  November 17, 2025
  Participants: David J. Earp, J.D., Ph.D., president and chief executive officer; Rob Lauzen, chief financial officer
  Location: London, UK

• Jefferies Global Healthcare Conference - London
  November 18-20, 2025
  Participants: David J. Earp, J.D., Ph.D., president and chief executive officer; Rob Lauzen, chief financial officer
  Location: London, UK

About Circle Pharma

Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop next-generation targeted therapies for cancer and other serious illnesses. The company’s proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies, including for historically undruggable targets. Circle Pharma’s pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. The company’s lead program, CID-078, is a cyclin A/B RxL inhibitor in Phase 1 clinical development for patients with advanced solid tumors. Circle Pharma is based in South San Francisco, CA. For additional information, please visit us at circlepharma.com and follow us on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251103229143/en/

Media:
Josie Butler
1AB
[email protected]

Investors:
Steve Klass
1AB
[email protected]

Source: Circle Pharma, Inc.

You May Also Be Interested In

• Norton Manx R Earns Landmark International Design Excellence Award for Reimagining the Superbike
• Monad Price Prediction Hits a Wall While Smart Wallets Rush Into the Pepeto Presale
• Top 3 Cryptos to Buy Now: XRP and Solana Explode While Pepeto Steals the Spotlight